EyePoint Pharmaceuticals, Inc. (EYPT) vs X4 Pharmaceuticals, Inc. (XFOR)
A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and X4 Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EYPT
EyePoint Pharmaceuticals, Inc.
$3.12HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
XFOR
X4 Pharmaceuticals, Inc.
$2.75HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — EYPT vs XFOR
growth of $100 · dividends reinvested · last 9yEYPT -75.4% (-14.4%/yr)XFOR -99.9% (-52.9%/yr)EYPT compounded faster over this window
Log scale — wide-divergence pair
EYPT XFOR
EYPT vs XFOR: by the numbers
- •EYPT is the larger company ($261M vs $259M market cap).
- •Both run net losses; XFOR's is the smaller (-568.80% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | EYPT | XFOR |
|---|---|---|
| P/S ratio | 93.64 | 16.34 |
| P/B ratio | 1.57 | 1.67 |
Profitability
| Metric | EYPT | XFOR |
|---|---|---|
| Gross margin | 93.41% | 81.22% |
| Operating margin | -775.98% | -247.44% |
| Net margin | -10994.73% | -568.80% |
| ROE | -184.27% | -57.98% |
| ROIC | -170.19% | -37.61% |
Growth (annualized)
| Metric | EYPT | XFOR |
|---|---|---|
| Revenue CAGR (5Y) | -41.05% | N/A |
| Total return CAGR (5Y) | -21.68% | -55.06% |
Frequently asked
- How have EYPT and XFOR total returns compared?
- Over the past 5 years, EYPT delivered -21.68% and XFOR delivered -55.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.